Updated recommendations for the use of varicella zoster immune globulin (VarIg) for the prevention of varicella in at-risk patients: An Advisory Committee Statement (ACS)

Highlights key information for immunization providers. VarIg is recommended for individuals who are at increased risk of severe varicella if significant exposure has occurred. These individuals include: susceptible pregnant women; newborn infants of mothers who develop varicella from 5 days before until 48 hours after delivery; selected neonates in neonatal or pediatric intensive-care settings; susceptible immunocompromised individuals, including susceptible HIV-infected persons and hematopoietic stem cell transplantation recipients.